Erratum: ROR nuclear receptors: structures, related diseases, and drug discovery (Acta Pharmacologica Sinica (2015) 36 (71-87) DOI: 10.1038/aps.2014.120);ROR nuclear receptors: Structures, related diseases, and drug discovery

Acta Pharmacologica Sinica

Volumn 36, Issue 1, 2015, Pages 71-87

  Zhang, Yan ^a   Luo, Xiao Yu ^a   Wu, Dong Hai ^a   Xu, Yong ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

autoimmune disease; metabolic disorder; nuclear receptor; rational drug design; retinoic acid receptor related orphan receptor

Indexed keywords

2 (4 (ETHYLSULFONYL)PHENYL) N (6 (3FLUOROPHENOXY) [1,1'-BIPHENYL] 3 YL)ACETAMIDE; 2 CHLORO 6 FLUORO N (1 ((4 FLUOROPHENYL) SULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 7 YL)BENZAMIDE; 2,4 DIFLUORO N (1 ((4-FLUOROPHENYL)SULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 7 YL) BENZENESULFONAMIDE; 20 ALPHA HYDROXYCHOLESTEROL; 25 HYDROXYCHOLESTEROL; 3 BETA HYDROXYL GROUP; 4 (1 (2 CHLORO 6 CYCLOPROPYLBENZOYL) 7 FLUORO 1 H INDAZOL 3 YL) 3 FLUOROBENZOIC ACID; AROMATIC AMIDE; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CHOLESTEROL SULFATE; DIGOXIN; HEXAFLUORO 2 PROPANOL; LIVER X RECEPTOR AGONIST; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; N (3,4 DIMETHOXYPHENYL) 1 ETHYL 2OXO 1,2 DIHYDROBENZO[CD]INDOLE 6 SULFANAMIDE; N (4 (4 ACETYLPIPERAZIN 1 YL)BENZYL) N ISOBUTYL 1 PHENYLMETHANESULFONAMIDE; N [1 (4 (1,1,1,3,3,3 HEXAFLUORO 2 HYDROXYPROPAN 2 YL)BENZYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACETAMIDE; N [4 (4 ACETYLPIPERAZIN 1 YL)BENZYL] N ISOBUTYL 1 PHENYLMETHANESULFONAMIDE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR BETA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STEARIC ACID; SULFONAMIDE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSOLIC ACID; LIGAND; ORPHAN NUCLEAR RECEPTOR;

AGONIST; ARTICLE; AUTOIMMUNE DISEASE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING FLUORIMETRY; FLUOROMETRY; GENETIC TRANSFECTION; HYDROGEN BOND; LABORATORY; LUCIFERASE ASSAY; METABOLIC DISORDER; MOLECULAR DOCKING; NEOPLASM; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REPORTER GENE; ANIMAL; DRUG DEVELOPMENT; HUMAN; METABOLISM; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; ORPHAN NUCLEAR RECEPTORS;

EID: 84920471444     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2015.2     Document Type: Erratum

References (103)

1. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
2. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-95.
3. Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, et al. Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev 2013; 65: 710-78.
4. Giguere V. Orphan nuclear receptors: from gene to function. Endocr Rev 1999; 20: 689-725.
5. Laudet V. Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor. J Mol Endocrinol 1997; 19: 207-26.
6. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5: 993-6.
7. Hummasti S, Tontonoz P. Adopting new orphans into the family of metabolic regulators. Mol Endocrinol 2008; 22: 1743-53.
8. Mohan R, Heyman RA. Orphan nuclear receptor modulators. Curr Top Med Chem 2003; 3: 1637-47.
9. Benoit G, Cooney A, Giguere V, Ingraham H, Lazar M, Muscat G, et al. International union of pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 2006; 58: 798-836.
10. Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal 2009; 7: e003.
11. Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-Morton S, et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000; 288: 2369-73.
12. Giguere V, Tini M, Flock G, Ong E, Evans RM, Otulakowski G. Isoformspecific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors. Genes Dev 1994; 8: 538-53.
13. Carlberg C, Hooft van Huijsduijnen R, Staple JK, DeLamarter JF, Becker-Andre M. RZRs, a new family of retinoid-related orphan receptors that function as both monomers and homodimers. Mol Endocrinol 1994; 8: 757-70.
14. Hirose T, Smith RJ, Jetten AM. ROR gamma: the third member of ROR/RZR orphan receptor subfamily that is highly expressed in skeletal muscle. Biochem Biophys Res Commun 1994; 205: 1976-83.
15. Hamilton BA, Frankel WN, Kerrebrock AW, Hawkins TL, FitzHugh W, Kusumi K, et al. Disruption of the nuclear hormone receptor RORalpha in staggerer mice. Nature 1996; 379: 736-9.
16. Steinmayr M, Andre E, Conquet F, Rondi-Reig L, Delhaye-Bouchaud N, Auclair N, et al. staggerer phenotype in retinoid-related orphan receptor alpha-deficient mice. Proc Natl Acad Sci USA 1998; 95: 3960-5.
17. Andre E, Gawlas K, Becker-Andre M. A novel isoform of the orphan nuclear receptor RORbeta is specifically expressed in pineal gland and retina. Gene 1998; 216: 277-83.
18. Andre E, Conquet F, Steinmayr M, Stratton SC, Porciatti V, Becker-Andre M. Disruption of retinoid-related orphan receptor beta changes circadian behavior, causes retinal degeneration and leads to vacillans phenotype in mice. EMBO J 1998; 17: 3867-77.
19. Medvedev A, Yan ZH, Hirose T, Giguere V, Jetten AM. Cloning of a cDNA encoding the murine orphan receptor RZR/ROR gamma and characterization of its response element. Gene 1996; 181: 199-206.
20. Jetten AM, Kurebayashi S, Ueda E. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol 2001; 69: 205-47.
21. Burris TP. Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock. Mol Endocrinol 2008; 22: 1509-20.
22. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol 2007; 14: 1207-13.
23. Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, Reid RA, et al. Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science 2007; 318: 1786-9.
24. Chang MR, Lyda B, Kamenecka TM, Griffin PR. Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor gamma is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol 2014; 66: 579-88.
25. Burris TP, Busby SA, Griffin PR. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 2012; 19: 51-9.
26. Chang MR, Rosen H, Griffin PR. RORs in autoimmune disease. Curr Top Microbiol Immunol 2014; 378: 171-82.
27. Marciano DP, Chang MR, Corzo CA, Goswami D, Lam VQ, Pascal BD, et al. The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARgamma, RORs, and Rev-erbs. Cell Metab 2014; 19: 193-208.
28. Solt LA, Burris TP. Action of RORs and their ligands in (patho) physiology. Trends Endocrinol Metab 2012; 23: 619-27.
29. Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011; 472: 491-4.
30. Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 2011; 472: 486-90.
31. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
32. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223: 87-113.
33. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008; 28: 29-39.
34. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-33.
35. Ivanov, II, Zhou L, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol 2007; 19: 409-17.
36. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9: 641-9.
37. Kang HS, Angers M, Beak JY, Wu X, Gimble JM, Wada T, et al. Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol Genomics 2007; 31: 281-94.
38. Lau P, Fitzsimmons RL, Raichur S, Wang SC, Lechtken A, Muscat GE. The orphan nuclear receptor, RORalpha, regulates gene expression that controls lipid metabolism: staggerer (SG/SG) mice are resistant to diet-induced obesity. J Biol Chem 2008; 283: 18411-21.
39. Mamontova A, Seguret-Mace S, Esposito B, Chaniale C, Bouly M, Delhaye-Bouchaud N, et al. Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. Circulation 1998; 98: 2738-43.
40. Chopra AR, Louet JF, Saha P, An J, Demayo F, Xu J, et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 2008; 322: 1395-9.
41. Kumar N, Kojetin DJ, Solt LA, Kumar KG, Nuhant P, Duckett DR, et al. Identification of SR3335 (ML-176): a synthetic ROR alpha selective inverse agonist. ACS Chem Biol 2011; 6: 218-22.
42. Zhu Y, McAvoy S, Kuhn R, Smith DI. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 2006; 25: 2901-8.
43. Wang Y, Solt LA, Kojetin DJ, Burris TP. Regulation of p53 stability and apoptosis by a ROR agonist. PLoS ONE 2012; 7: e34921.
44. Du J, Xu R. RORalpha, a potential tumor suppressor and therapeutic target of breast cancer. Int J Mol Sci 2012; 13: 15755-66.
45. Stehlin C, Wurtz JM, Steinmetz A, Greiner E, Schule R, Moras D, et al. X-ray structure of the orphan nuclear receptor RORbeta ligandbinding domain in the active conformation. EMBO J 2001; 20: 5822-31.
46. Stehlin-Gaon C, Willmann D, Zeyer D, Sanglier S, Van Dorsselaer A, Renaud JP, et al. All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta. Nat Struct Biol 2003; 10: 820-5.
47. Kallen J, Schlaeppi JM, Bitsch F, Delhon I, Fournier B. Crystal structure of the human ROR alpha ligand binding domain in complex with cholesterol sulfate at 2.2 angstrom. J Biol Chem 2004; 279: 14033-38.
48. Kallen JA, Schlaeppi JM, Bitsch F, Geisse S, Geiser M, Delhon I, et al. X-ray structure of the hROR alpha LBD at 1.63 angstrom: Structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of ROR alpha. Structure 2002; 10: 1697-707.
49. Jin L, Martynowski D, Zheng S, Wada T, Xie W, Li Y. Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma. Mol Endocrinol 2010; 24: 923-9.
50. Fujita-Sato S, Ito S, Isobe T, Ohyama T, Wakabayashi K, Morishita K, et al. Structural basis of digoxin that antagonizes ROR gamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. J Biol Chem 2011; 286: 31409-17.
51. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14: 2831-8.
52. Yang T, Liu Q, Cheng YB, Cai W, Ma YL, Yang LQ, et al. Discovery of tertiary amine and indole derivatives as potent ROR gamma t inverse agonists. ACS Med Chem Lett 2014; 5: 65-8.
53. Wang YH, Cai W, Zhang GF, Yang T, Liu Q, Cheng YB, et al. Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl) amides and N-(5-(arylcarbonyl) thiophen-2-yl)amides as potent ROR gamma t inhibitors. Bioorg Med Chem 2014; 22: 692-702.
54. Fauber BP, Rene O, de Leon Boenig G, Burton B, Deng Y, Eidenschenk C, et al. Reduction in lipophilicity improved the solubility, plasmaprotein binding, and permeability of tertiary sulfonamide RORc inverse agonists. Bioorg Med Chem Lett 2014 ; 24: 3891-7.
55. Ullman EF, Kirakossian H, Switchenko AC, Ishkanian J, Ericson M, Wartchow CA, et al. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clin Chem 1996; 42: 1518-26.
56. Ullman EF, Kirakossian H, Singh S, Wu ZP, Irvin BR, Pease JS, et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci USA 1994; 91: 5426-30.
57. Glickman JF, Wu X, Mercuri R, Illy C, Bowen BR, He Y, et al. A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J Biomol Screen 2002; 7: 3-10.
58. Wang S, Wang Z, Lin S, Zheng W, Wang R, Jin S, et al. Revealing a natural marine product as a novel agonist for retinoic acid receptors with a unique binding mode and inhibitory effects on cancer cells. Biochem J 2012; 446: 79-87.
59. Jin L, Feng X, Rong H, Pan Z, Inaba Y, Qiu L, et al. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun 2013; 4: 1937.
60. Jin L, Lin S, Rong H, Zheng S, Jin S, Wang R, et al. Structural basis for iloprost as a dual peroxisome proliferator-activated receptor alpha/delta agonist. J Biol Chem 2011; 286: 31473-9.
61. Malapaka RR, Khoo S, Zhang J, Choi JH, Zhou XE, Xu Y, et al. Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem 2012; 287: 183-95.
62. Zhang Y, Xue X, Jin X, Song Y, Li J, Luo X, et al. Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORgamma inhibitors using virtual screening, synthesis and biological evaluation. Eur J Med Chem 2014; 78: 431-41.
63. Zhou XE, Suino-Powell KM, Xu Y, Chan CW, Tanabe O, Kruse SW, et al. The orphan nuclear receptor TR4 is a vitamin A-activated nuclear receptor. J Biol Chem 2011; 286: 2877-85.
64. Cheung V, Chua G, Batada NN, Landry CR, Michnick SW, Hughes TR, et al. Chromatin-and transcription-related factors repress transcription from within coding regions throughout the Saccharomyces cerevisiae genome. PLoS Biol 2008; 6: e277.
65. Fedorov O, Niesen FH, Knapp S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. Methods Mol Biol 2012; 795: 109-18.
66. Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 2001; 6: 429-40.
67. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2007; 2: 2212-21.
68. Matulis D, Kranz JK, Salemme FR, Todd MJ. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry (Mosc) 2005; 44: 5258-66.
69. Senisterra GA, Markin E, Yamazaki K, Hui R, Vedadi M, Awrey DE. Screening for ligands using a generic and high-throughput lightscattering-based assay. J Biomol Screen 2006; 11: 940-8.
70. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ Jr, Wasney GA, et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci USA 2006; 103: 15835-40.
71. Holdgate GA, Ward WH. Measurements of binding thermodynamics in drug discovery. Drug Discov Today 2005; 10: 1543-50.
72. Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007; 104: 20523-8.
73. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res 2013; 73: 3336-46.
74. Sekiguchi M, Kobashigawa Y, Moriguchi H, Kawasaki M, Yuda M, Teramura T, et al. High-throughput evaluation method for drug association with pregnane X receptor (PXR) using differential scanning fluorometry. J Biomol Screen 2013; 18: 1084-91.
75. DeSantis K, Reed A, Rahhal R, Reinking J. Use of differential scanning fluorimetry as a high-throughput assay to identify nuclear receptor ligands. Nucl Recept Signal 2012; 10: e002.
76. Blumberg B, Evans RM. Orphan nuclear receptors-new ligands and new possibilities. Genes Dev 1998; 12: 3149-55.
77. Wilkinson J, Hallis T, Hermanson S, Bi K. Development and validation of a cell-based assay for the nuclear receptor retinoid-related orphan receptor gamma. Assay Drug Dev Technol 2011; 9: 125-35.
78. Wilkinson JM, Hayes S, Thompson D, Whitney P, Bi K. Compound profiling using a panel of steroid hormone receptor cell-based assays. J Biomol Screen 2008; 13: 755-65.
79. Paguio A, Stecha P, Wood KV, Fan F. Improved dual-luciferase reporter assays for nuclear receptors. Curr Chem Genomics 2010; 4: 43-9.
80. Ou-Yang SS, Lu JY, Kong XQ, Liang ZJ, Luo C, Jiang H. Computational drug discovery. Acta Pharmacol Sin 2012; 33: 1131-40.
81. Zheng M, Liu X, Xu Y, Li H, Luo C, Jiang H. Computational methods for drug design and discovery: focus on China. Trends Pharmacol Sci 2013; 34: 549-59.
82. Huang H, Yu Y, Gao Z, Zhang Y, Li C, Xu X, et al. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists. J Med Chem 2012; 55: 7037-53.
83. Fu J, Si P, Zheng M, Chen L, Shen X, Tang Y, et al. Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on phase shape and induced fit docking. Bioorg Med Chem Lett 2012; 22: 6848-53.
84. Shen J, Jiang J, Kuang G, Tan C, Liu G, Huang J, et al. Discovery and structure-activity analysis of selective estrogen receptor modulators via similarity-based virtual screening. Eur J Med Chem 2012; 54: 188-96.
85. Shen J, Tan C, Zhang Y, Li X, Li W, Huang J, et al. Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening. J Med Chem 2010; 53: 5361-5.
86. Xu T, Wang XH, Zhong B, Nurieva RI, Ding S, Dong C. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of ROR lambda t protein. J Biol Chem 2011; 286: 22707-10.
87. Kumar N, Solt LA, Conkright JJ, Wang YJ, Istrate MA, Busby SA, et al. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a novel retinoic acid receptor-related Orphan receptor-alpha/gamma inverse agonist. Mol Pharmacol 2010; 77: 228-36.
88. Wang YJ, Kumar N, Nuhant P, Cameron MD, Istrate MA, Roush WR, et al. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors ROR alpha and ROR gamma. ACS Chem Biol 2010; 5: 1029-34.
89. Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, et al. Identification of SR2211: a potent synthetic ROR gamma-selective Modulator. ACS Chem Biol 2012; 7: 672-7.
90. Solt LA, Kumar N, He YJ, Kamenecka TM, Griffin PR, Burris TP. Identification of a selective ROR gamma ligand that suppresses T(H)17 cells and stimulates T regulatory cells. ACS Chem Biol 2012; 7: 1515-9.
91. Huh JR, Englund EE, Wang H, Huang RL, Huang PX, Rastinejad F, et al. Identification of potent and selective diphenylpropanamide ROR gamma Inhibitors. ACS Med Chem Lett 2013; 4: 79-84.
92. Khan PM, El-Gendy BEDM, Kumar N, Garcia-Ordonez R, Lin L, Ruiz CH, et al. Small molecule amides as potent ROR-gamma selective modulators. Bioorg Med Chem Lett 2013; 23: 532-6.
93. Gaweco A, Tilley JW, Walker J, Palmer S, Blinn J. Preparation of quinoline compounds as ROR (retinoid-related orphan receptor) modulators and their therapeutic uses. WO 2013/159095. Apr 22. 2013.
94. Glick GD, Toogood PL, Romero AG, Vanhuis CA, Aicher TD, Kaub C, et al. Tetrahydroquinoline and related bicyclic compounds for inhibition of ROR activity and the treatment of disease and their preparation. WO 2012/064744. Nov 8. 2012.
95. Aicher TBK, Lapointe B, Simov V, Stein K, Thomas W, Toogood PvHC, et al. Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease. WO 2013/169704. Nov 14. 2013.
96. Barr KJ, Maclean J, Zhang H, Beresis Rt, Zhang D. 3-Cyclohexenyl and cyclohexyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof. WO2014/028597. Feb 20. 2014.
97. Zhang W, Zhang J, Fang LP, Zhou L, Wang S, Xiang ZJ, et al. Increasing human Th17 differentiation through activation of orphan nuclear receptor retinoid acid-related orphan receptor gamma (ROR gamma) by a class of aryl amide compounds. Mol Pharmacol 2012; 82: 583-90.
98. Chaudhari SS, Thomas A, Khairatkar-Joshi N, Bajpai M. Preparation of aryl and heteroaryl amide compounds as RORγt modulator. WO 2013/171729. Aug 29. 2013.
99. Birault VCAJ, Harrison S, Le J, Sulfonamide, Rabino M. Sulfonamide Compounds and their use in the modulation retinoid-related orphan receptor. WO 2013/045431. Apr 4. 2013.
100. Birault V, Campbell AJ, Harrison S, Le J, Shukla L. Preparation of heterocyclic benzenesulfonamides as RORγ modulators for treatment of inflammatory, metabolic, or autoimmune disorders. WO 2013/160419. Apr 25. 2013.
101. Fauber BP, Rene O, Burton B, Everett C, Gobbi A, Hawkins J, et al. Identification of tertiary sulfonamides as RORc inverse agonists. Bioorg Med Chem Lett 2014; 24: 2182-7.
102. Kotoku M, Maeba T, Seki N, Hirashima S, Fujioka S, Obika S, et al. Preparation of isoxazoles and their use as ROR-γ antagonists and pharmaceuticals. WO 2014/065413. Oct 25. 2014.
103. Fauber BP, de Leon Boenig G, Burton B, Eidenschenk C, Everett C, Gobbi A, et al. Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc. Bioorg Med Chem Lett 2013; 23: 6604-9.